Generic Line: Subscribe Now!

Buy Now

For over 25 years, Generic Line has been the leading resource of accurate, up-to-date news and analysis on FDA policies affecting generic drugs and drug patents.

Each monthly issue keeps you and your firm up to date on crucial regulatory, legislative and business changes, including the latest on:

  • The establishment of a biosimilars approval pathway
  • What Strategies are most successful in challenging blockbuster brands
  • The FTC's growing efforts to stop pay-for-delay agreements.

PLUS: in every issue, you get links to additional key documents that support Generic Line’s articles, such as FDA guidances, warning letters and 483s, rules, full texts of proposed legislation and more.

There’s absolutely no risk to you. You get our 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Generic Line, you may cancel your subscription and receive a full refund. No questions asked.

So, why wait? Become a subscriber to Generic Line today. It couldn’t be easier.

Monthly, 12 issues/year